护心通络方浓缩丸对稳定性心绞痛气虚血瘀证患者血清OX-LDL、TNF-α、IL-6的影响

发布时间：2018-06-18 20:56

本文选题：护心通络方浓缩丸 + 稳定性心绞痛　；参考：《湖南中医药大学》2016年硕士论文

【摘要】：目的：研究护心通络方浓缩丸治疗稳定性心绞痛气虚血瘀证患者的临床疗效及其对患者血清OX-LDL、TNF-α、IL-6水平的影响。方法：将符合纳入与排除标准的60例患者按照随机对照原则进行分配,分为治疗组和对照组各30例,两组患者在性别、年龄、病程、病情程度方面进行比较均无明显差异(P0.05),两组间具有齐同可比性。对照组给予西医常规治疗,治疗组在对照组的基础上加用护心通络方浓缩丸,两组患者疗程均为4周。观察两组患者治疗前后中医证候积分、心绞痛发作频率、持续时间、硝酸甘油使用量、中医证候疗效、血清0X-LDL、TNF-α、IL-6水平的改变,进行对比。结果：1.两组治疗后在胸痛、胸闷、心悸、气短、神疲乏力中医症候积分较治疗前改善,差异具有统计学意义(P0.05),同时,治疗组治疗后在以上症候积分较对照组下降,差异有统计学意义(P0.05)。2.两组治疗后心绞痛发作频率、持续时间、硝酸甘油使用量、中医证候疗效方面两组均较治疗前减少,同时,治疗组治疗后在胸痛、胸闷、心悸、气短、神疲乏力症候积分较对照组下降,差异有统计学意义(P0.05),且治疗组治疗后较对照组改善明显(P0.05)。3.两组治疗后血清OX-LDL、TNF-α、IL-6水平较治疗前均有下降,且治疗组治疗后较对照组下降明显(P0.05)。4.治疗组治疗后临床疗效、中医症候疗效均优于对照组,差异有统计学意义(P0.05)。5.两组患者治疗期间均未出现不良反应事件。结论：1.稳定性心绞痛气虚血瘀证患者血清OX-LDL、 TNF-α、IL-6水平表达升高,经药物治疗后,均得到下降,提示0X-LDL、TNF-α、IL-6在稳定性心绞痛的发病中存在异常。2.护心通络方浓缩丸对稳定性心绞痛具有较好的疗效,其能改善稳定性心绞痛患者的中医证候积分,减少心绞痛发作频率、持续时间、硝酸甘油使用量,降低稳定性心绞痛患者的血清OX-LDL、TNF-α、IL-6水平,这可能是护心通络方浓缩丸对稳定性心绞痛的作用机理。3.护心通络方浓缩丸治疗稳定性心绞痛患者无不良反应发生。
[Abstract]:Objective: to study the clinical effect of Huxin Tongluo decoction (Huxin Tongluo decoction) in treating stable angina pectoris with Qi deficiency and blood stasis syndrome and its effect on the serum level of TNF- 伪 and IL-6 in patients with OX-LDL- 伪. Methods: sixty patients who met the criteria of inclusion and exclusion were divided into treatment group (n = 30) and control group (n = 30) according to the principle of randomized control. There was no significant difference in the degree of illness between the two groups. The control group was treated with routine western medicine, the treatment group was treated with Huxin Tongluo decoction concentrated pill on the basis of the control group, the two groups were treated for 4 weeks. The changes of TCM syndromes score, angina attack frequency, duration, nitroglycerin usage, TCM syndromes and serum 0X-LDL- 伪 IL-6 levels before and after treatment were observed and compared between the two groups. The result is 1: 1. After treatment, the scores of chest pain, chest tightness, palpitation, shortness of breath and fatigue were improved in the two groups, and the difference was statistically significant (P 0.05). At the same time, the score of the above symptoms in the treatment group was lower than that in the control group, and the difference was statistically significant. The frequency and duration of angina pectoris attack, the usage of nitroglycerin, the curative effect of TCM syndrome were decreased in both groups after treatment. At the same time, the treatment group had chest pain, chest tightness, palpitation, shortness of breath after treatment. The score of fatigue symptoms was lower than that of the control group, the difference was statistically significant (P 0.05), and the treatment group was significantly improved than the control group (P 0.05). 3. After treatment, the serum levels of OX-LDL- 伪 TNF- 伪 IL-6 in both groups were lower than those before treatment, and the levels of TNF- 伪 IL-6 in the treatment group were significantly lower than those in the control group. The treatment group after the treatment of clinical efficacy, traditional Chinese medicine symptoms are better than the control group, the difference is statistically significant P 0.05. 5. There were no adverse events in both groups. Conclusion 1. The serum levels of OX-LDLand TNF- 伪 IL-6 in patients with stable angina pectoris with Qi deficiency and blood stasis syndrome increased, and all decreased after drug treatment, suggesting that 0X-LDL- 伪 TNF- 伪 IL-6 is abnormal in the pathogenesis of stable angina pectoris. Huxin Tongluo prescription concentrated pill has better curative effect on stable angina pectoris. It can improve TCM syndromes integral of patients with stable angina pectoris, reduce angina pectoris attack frequency, duration, nitroglycerin usage, Decrease of serum OX-LDL- 伪 TNF- 伪 IL-6 level in patients with stable angina pectoris, which may be the action mechanism of Huxin Tongluo concentrated pill on stable angina pectoris. No adverse reactions occurred in patients with stable angina pectoris treated with Huxin Tongluo decoction concentrated pills.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】